TRANSBIG
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2004
- Initiating Organization: Breast International Group
- Initiator Type: Industry
- Disease focus:
Cancer - Location: Europe
Abstract
TRANSBIG comprises 28 world-class institutions in 11 countries. Each participating organization brings with it expertise that ranges from specialization in cutting-edge biomedical technologies and cancer treatment programs to representing patient groups and supporting cancer societies. Among its many strengths is the fact that TRANSBIG is linked to an already existing network of groups from around the world that conduct clinical breast cancer trials together – the Breast International Group (BIG).
Mission
The main objectives of TRANSBIG were:
to accelerate the way laboratory discoveries for breast cancer “translate” into treatments for patients (translational research)
to advance personalized treatment for breast cancer patients
to strengthen and facilitate collaboration in translational breast cancer research in Europe and internationally
Structure & Governance
The consortium is governed by Breast International Group.
Financing
Funding from the European Commission under Framework Programme VI (FP6)
Impact/Accomplishment
Click here for a description of consortium accomplishments
Links/Social Media Feed
Homepage |
http://www.breastinternationalgroup.org/our-research/research-pro/transbig/ |
Points of Contact
Breast International Group (BIG)-aisbl
Blvd de Waterloo 121
B-1000 Brussels | Belgium
VAT BE 0468 176 240
Sponsors & Partners
59 MEMBER GROUPS COVERING 55+ COUNTRIES |